References
Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318(5): 432–42.
Rauen T, Eitner F, Fitzner C, et al. STOP-IgAN investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–36.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 3(Suppl):1–150.
Yang M, Xu G, Ling L, et al. Performance of the creatinine and cystatin C-based equations for estimation of GFR in Chinese patients with chronic kidney disease. Clin Exp Nephrol. 2017;21(2):236–46.
Bökenkamp A, Laarman CA, Braam KI, et al. Effect of corticosteroid therapy on low-molecular weight protein markers of kidney function. Clin Chem. 2007;53(12):2219–21.
Acknowledgements
This work was supported by grants from Chinese Society of Nephrology (14050430580).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No potential conflict of interest relevant to this letter was reported.
About this article
Cite this article
Zou, Y., Yang, M. & Du, X. New insight into the management of IgA nephropathy. Clin Exp Nephrol 22, 1442–1443 (2018). https://doi.org/10.1007/s10157-018-1555-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-018-1555-5